Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Chronic Hepatitis B Infection Clinical Trial

Official title:
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Status Completed

Clinical Trial Summary

This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05355467
Study type	Interventional
Source	Mylan (Taiwan) Ltd
Contact
Status	Completed
Phase	Phase 4
Start date	August 21, 2019
Completion date	July 13, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03329820` - Quality of Life and Health Utility of Patients With CHB Infections	N/A
Recruiting	`NCT04030039` - Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Recruiting	`NCT03210467` - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy	N/A
Recruiting	`NCT03210493` - The Changes of Treg Cells Frequency and Function During Antiviral Therapy	N/A
Recruiting	`NCT03209011` - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy	Phase 4
Recruiting	`NCT03209037` - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy	Phase 4
Recruiting	`NCT03210506` - The Changes of Cytokines During Antiviral Therapy	N/A
Recruiting	`NCT03208998` - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy	Phase 4
Recruiting	`NCT04638439` - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection	Phase 1
Recruiting	`NCT03587467` - Study on Gut Microbiota in Chronic HBV Infected Patients
Recruiting	`NCT04135235` - Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B